Skip to main content

  • Drug-Eluting Versus Bare Metal Stents in Saphenous Vein Graft Intervention: An Updated Comprehensive Meta-Analysis of Randomized Trials

    • Posted: 10/03/2019
    • Author:

      Sukhdeep Bhogal, Hemang B. Panchal, Jayant Bagai, Subhash Banerjee, Emmanouil S. Brilakis, Debabrata Mukherjee, Gautam Kumar, Madhan Shanmugasundaram and Timir K. Paul

    • 2019CRM

    Highlights

    • Considering the conflicting results of previous meta-analysis, we performed a comprehensive meta-analysis including a new RCT and long-term data of ISAR-CABG, both published in 2018, comparing the efficacy and safety of DES versus BMS for SVG-PCI with the longest follow up.
    • Our meta-analysis shows that short-term follow up (mean 11 months) is associated with lower rate of MACE, TVR and binary in-stent restenosis in DES as compared with BMS. However, this benefit was lost on long-term follow up with a mean follow up 35.5 months.
    • Overall, during a mean follow up of 32.1 months, there was no significant difference in the risk of MACE, cardiovascular mortality, all-cause mortality, MI, stent thrombosis, TVR and TLR between DES and BMS.

    Abstract

    Background

    Drug eluting stents (DES) are preferred over bare metal stents (BMS) for native coronary artery revascularization unless contraindicated. However, the preferred stent choice for saphenous venous graft (SVG) percutaneous coronary interventions (PCI) is unclear due to conflicting results.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details